Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results
What Lucid Diagnostics (LUCD) Said on Its Q3 Earnings Call
Lucid Diagnostics Inc. (LUCD) Q3 2026 Earnings Call Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q3 Loss, Lags Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2026 Financial Results
Mettler-Toledo (MTD) Surpasses Q3 Earnings and Revenue Estimates
Lucid Diagnostics Recognized as a GenomeWeb Best Place to Work for Second Consecutive Year
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study
PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026
Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026
Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing
Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways
Lucid Diagnostics Eyes Medicare Catalyst for EsoGuard Growth
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
Lucid Diagnostics Q2 Earnings Call Highlights
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test